ArticlePublic health weekly report2026
Five-year Incidence Trends and the Status of Major Rare Diseases in 2023 in the 「Annual Report on the Rare Disease Patients in Korea」.
Article in Public health weekly report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study analyzed 5-year trends in rare disease incidence, deaths, and medical expenditures in the Republic of Korea using the 「Annual Report on the Rare Disease Patients in Korea」 (the Annual Report), with particular attention to the 2023 incidence figures by age, province, and frequently occurring diseases. Methods: This retrospective descriptive study used data from the Annual Report from 2019 to 2023. The annual numbers of newly registered rare disease cases and of deaths and the figures for healthcare utilization were analyzed, with particular attention to the incidence status in 2023. Results: Newly registered rare disease cases remained at around 50,000 annually before rising to 62,420 in 2023, with deaths and medical expenditures also increasing. In 2023, the incidence was highest among individuals in their 60s and those in the Gyeonggi-do region. Idiopathic pulmonary fibrosis and systemic lupus erythematosus with organ or system involvement were the most common rare diseases among males and females, respectively. Crohn's disease of the small and large intestine was the most frequent among those in their 10s and 20s, autosomal dominant polycystic kidney disease among those in their 30s to 50s, and idiopathic pulmonary fibrosis among those aged 60 and older, which last also incurred the highest total annual medical expenditure. Conclusions: The Annual Report has enhanced analytical accuracy and comprehensiveness through data refinement and statistical expansion. Future efforts should be directed to a transition from incidence-centered statistics to the establishment of a longitudinal data infrastructure that records incidence rates, survival rates, and the overall prevalence of rare diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.